Preparation of D-phenylglycinyl derivatives of cefuroxime as double ester prodrugs

Chinese Pharmaceutical Journal

Volumn 49, Issue 3, 1997, Pages 195-205

  Lee, Jia Shuai ^a   Sun, Chi Hua ^a   Wang, Hui Po ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Cefuroxime prodrugs; D Phenylglycine

Indexed keywords

CEFUROXIME; CEFUROXIME PHENYLGLYCINE DERIVATIVE; PRODRUG; UNCLASSIFIED DRUG;

ALKYLATION; ANIMAL TISSUE; ARTICLE; DRUG DEGRADATION; DRUG STABILITY; DRUG SYNTHESIS; INTESTINE MUCOSA; MALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PH; RAT; STEREOISOMERISM;

EID: 0031460106     PISSN: 10161015     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Garzone, P.; Lyon, J.; Yu, V. L. Third Generation and Investigational Cephalosporins: Structure-activity Relationships and Pharmacokinetic Review. Drug Intell. Clin. Pharm. 1983, 17, 507-515.
2. Gruneberg, R. N. The Alexander Project: Using In-vitro Susceptibility Data for Choosing Empirical Therapy in LRTI. J. Antimicrob. Chemother. 1996, 38 Suppl A, 155-170.
3. Foord, R. D. Cefuroxime: Human Pharmacokinetics. Antimicrob. Agents Chemother. 1976, 9, 741-747.
4. Perry, C. M.; Brogden, R. N. Cefuroxime Axetil. A Review of its Antibacterial Activity, Pharmacokinetic Properties and Therapeutic Efficacy. Drugs 1996, 52, 125-158.
5. Malfair, S. C.; Frighetto, L.; Nickoloff, D. M.; Martinusen, S. M.; Jewesson, P. J. Evaluation of the Use of Cefuroxime and Cefuroxime Axetil in an Intravenous-Oral Stepdown Program. Ann. Pharmacother. 1996, 30, 337-342.
6. Gooch, W. M. 3rd.; Blair, E.; Puopolo, A.; Paster, Z.; Schwartz, R. H.; Miller, H. C.; Smyre, H. L.; Giguere, G. C.; Collins, J. J. Clinical Comparison of Cefuroxime Axetil Suspension and Amoxicillin/Clavulanate Suspension in the Treatment of Pediatric Patients with Acute Otitis Media with Effusion. Clin. Ther. 1995, 17, 838-851.
7. Aujard, Y.; Brahimi, N.; Chiche, D.; Bingen, E. Comparative Efficacy And Safety of Four-Day Cefuroxime Axetil and Ten-Day Penicillin Treatment of Group A Beta-Hemolytic Streptococcal Pharyngitis Pediatr. Infect. Dis. J. 1995, 14, 295-300.
8. Quintiliani, R. Cefixime in the Treatment of Patients with Lower Respiratory Tract Infections: Results of US Clinical Trials. Clin. Ther. 1996, 18, 373-390.
9. Wyeth, J. W.; Pounder; R. E.; Duggan, A. E.; O'Morain, C. A.; Schaufelberger, H. D.; De Koster; E. H.; Rauws, E. A.; Bardhan, K. D.; Gilvarry, J.; Buckley, M. J.; Gummett, P. A.; Logan, R. P. The Safety and Efficacy of Ranitidine Bismuth Citrate in Combination with Antibiotics for the Eradication of Helicobacter Pylori. Aliment. Pharm. Therap. 1996, 10, 623-630.
10. Reilly, T. G.; Ayres, R.C.; Poxon, V.; Walt, R. P. Helicobacter Pylori Eradication in a Clinical Setting: Success Rates and the Effect on the Quality of Life in Peptic Ulcer. Aliment. Pharm. Therap. 1995, 9, 483-490.
11. Bai, J. P. F.; Amidon, G. L. Structural Specificity of Mucosal-Cell Transport and Metabolism of Peptide Drugs: Implication for Oral Peptide Drug Delivery. Pharm. Res. 1992, 9, 969-978.
12. Amidon, G. L.; Lee, H. J. Absorption of Peptide and Peptidomimetic Drugs. Annu. Rev. Pharmacol. Toxicol. 1994, 34, 321-341.
13. +-Coupled Uphill Transport of Aminocephalosporins via the Dipeptide Transport System in Rabbit Intestinal Brush-Border Membranes. J. Biol. Chem. 1986, 261, 14130-14134.
14. Sinko, P. J.; Amidon, G. L. Characterization of the Oral Absorption of β-Lactam Antibiotics II: Competitive Absorption and Peptide Carrier Specificity. J. Pharm. Sci. 1989, 78, 723-727.
15. Dantzig, A. H.; Bergin, L. Uptake of Cephalosporin, Cephalexin, by a Dipeptide Transport Carrier in the Human Intestinal Cell Line, Caco-2. Biochim. Biophys. Acta. 1990, 1027, 211-217.
16. Wang, H. P.; Lu, H. H.; Lee, J. S.; Cheng, C. Y.; Mah J. R.; Hsu, W. L.; Yen, C. F.; Lin, C. J.; Kuo. H. S. Intestinal Absorption Studies on Peptido Mimetic Prodrugs of α-Methyidopa. J. Pharm. Pharmacol. 1996, 48, 270-276.
17. Wang, H. P.; Lee, J. S.; Tsai, M. C.; Lu, H. H.; Hsu, W. L. Synthesis, Intestinal Absorption and Pharmacological Activities of a Novel Tripeptide Mimetic Dopamine Prodrug. Bioorg. Med. Chem. Lett. 1995, 5, 2195-2198.
18. Wang, H. P.; Lee, J. S.; Tsai, M. C.; Lu, H. H.; Hu, O. Y. P.; Lo, W. L. Novel Di and Tripeptide Mimetic Compounds for Parkinson's Disease. U.S. Patent 08/602,361. 1996.
19. Hu, M.; Subramanian, P.; Mosberg, H. I.; Amidon, G. L. Use of the Peptide Carrier System to Improve the Intestinal Absorption of L-α-Methyidopa: Carrier Kinetics, Intestinal Permeabilities, and in vitro Hydrolysis of Dipeptide Derivatives of L-α-Methyidopa. Pharm. Res. 1989, 6, 66-70.
20. Fujimoto, K.; Ishihara, S.; Yanagisawa H.; Ide, J.; Nakayama, E.; Nakao H.; Sugawara, S.; Iwata M. Studies on Orally Active Cephalosporin Esters. J. Antibiotics. 1987, 40, 370-384.
21. Wang, H. P.; Cheng, C. Y.; Ma, J. R.; Lee, J. S. Synthesis of α-Methyidopa Prodrugs Containing Dipeptide Moieties as Tools for Intestinal Delivery. J. Chin. Chem. Soc. 1995, 42, 561-567.
22. Kyoto Pharmaceutical Industries Ltd., Japan Kokai Tokkyo Koho JP 59 25,373 [84 25,373] (Cl. C07C161/00), 1984; Chem. Abstr. 1984, 101, 54799g.
23. Hussain, A. A.; Saab, A. N.; Dittet, L. W. Isomerization of Cephalosporin Ester: Implication for the Prodrug Ester Approach to Enhancing the Oral Bioavailability of Cephalosporin. J. Pharm. Sci. 1988, 77, 906-907.
24. Stella, V. J.; Richter, W. F.; Chong Y. H. On the Mechanism of Isomerization of Cephalosporin Ester. J. Pharm. Sci. 1990, 79, 185-187.